Objective: To determine the visual acuity outcome at age 10 years for children younger than 7 years when enrolled in a treatment trial for moderate amblyopia.
A
MBLYOPIA IS A LEADING cause of monocular visual impairment. 1, 2 Treatments such as refractive correction, patching, and atropine eyedrops to the sound eye have been shown to improve the visual acuity of the amblyopic eye. [3] [4] [5] Regression occurs in some patients after cessation of treatment for amblyopia, thereby reducing the lifetime benefit of therapy. [6] [7] [8] [9] [10] [11] [12] Longterm outcome data after completion of amblyopia treatment are limited.
The Pediatric Eye Disease Investigator Group (PEDIG) conducted a randomized trial that compared patching (6 hours to full-time daily in the sound eye) with atropine (1% daily in the sound eye) as treatment for moderate amblyopia (visual acuity, 20/40-20/100) in children younger than 7 years. 3 After 6 months, approximately 3 logMAR (logarithm of the minimum angle of resolution) lines of improvement in the visual acuity of the amblyopic eyes were present in both treatment groups. After the initial 6-month treatment phase, the investigators, at their discretion, could switch, combine, or adjust the dosage of treatments. Between 6 months and 2 years, additional visual acuity improvement occurred in both original treatment groups, averaging 0.7 log-MAR line. However, only 50% of amblyopic eyes had a visual acuity of 20/25 or better at the 2-year outcome. 13 In this report, we evaluate the visual acuity of the amblyopic and sound eyes and stereoacuity in the children from this trial when examined at age 10 years.
METHODS
The full study protocol has been detailed in prior publications. 3, 13 A brief summary of the protocol follows. Eligibility criteria for the randomized trial included age younger than 7 years, visual acuity in the amblyopic eye of See also page 1071 20/40 to 20/100, visual acuity in the sound eye of 20/40 or better, interocular acuity difference of 3 or more logMAR lines, and the presence or history of an amblyogenic factor that met study-specified criteria for strabismus and/or anisometropia. 3 Children were randomized to either patching (6 hours to full-time every day at investigator discretion) or atropine (1%, 1 drop once daily). During the first 6 months, the children maintained their randomized treatment. A protocol-specified masked outcome examination was conducted 6 months after randomization. Between 6 months and 2 years, the protocol allowed amblyopia treatment at investigator discretion but specified that patients were to be examined at least once every 6 months, with another masked outcome examination performed 2 years after randomization.
At the 2-year visit, parents of patients from a subset of participating sites (those with Ͼ5 patients enrolled and continuing with other PEDIG protocols) were invited to enter a longterm extension phase. The protocol and informed consent forms were approved by institutional review boards. Study oversight was provided by an independent data and safety monitoring committee. Written informed consent was obtained from the parent or guardian to continue follow-up with annual examinations through age 10 years and a future examination at age 15 years. All treatment prescribed during this phase was determined by the investigator. A total of 188 patients consented to participate in the extension phase. Testing at the age 10 years examination included measurement of visual acuity, cycloplegic refraction (if not measured within the prior 6 months), assessment of ocular alignment using the simultaneous prism and cover test at distance and near fixation, and an assessment of stereoacuity with the Randot Preschool Stereoacuity Test (Stereo Optical Company, Chicago, Illinois).
VISUAL ACUITY TESTING
Visual acuity was measured by a study-certified vision tester with an electronic modification of the testing protocol developed for the Early Treatment Diabetic Retinopathy Study (E-ETDRS).
14 Acuity testing was repeated if the visual acuity score was worse than 20/20 (Ͻ83 letters) and there was a difference between the cycloplegic refraction and the correction used for testing that met 1 or more of the following: (1) a 0.25-diopter (D) or greater increase in hyperopia, (2) a 0.25-D or greater increase in myopia, (3) a 0.25-D or greater change in cylinder power, (4) a 10°or greater change in axis, or (5) an increase in hyperopia or a decrease in myopia that would lead the investigator to change the patient's refractive correction.
During the initial phase of the study (through 2 years of followup), visual acuity was measured with the single-surrounded HOTV Amblyopia Treatment Study protocol. 15 To explore the difference in the visual acuity measured with the HOTV and E-ETDRS methods, at the first post-2-year visit, visual acuity was measured by both methods on the same day in 142 patients. The mean age at testing was 9.0 years (age range, 5.6-11.9 years). The amblyopic eye visual acuity was the same on both tests in 55 patients (39%), 1 line better with HOTV in 46 (32%), 2 or more lines better with HOTV in 29 (20%), 1 line better with E-ETDRS in 10 (7%), and 2 or more lines better with E-ETDRS in 2 (1%). The sound eye visual acuity was the same in 82 patients (58%), 1 line better with HOTV in 40 (28%), 2 or more lines better with HOTV in 5 (4%), 1 line better with E-ETDRS in 13 (9%), and 2 or more lines better with E-ETDRS in 2 (1%). The interocular difference was the same in 50 patients (35%), 1 line smaller with HOTV in 45 (32%), 2 or more lines smaller with HOTV in 21 (15%), 1 line smaller with E-ETDRS in 21 (15%), and 2 or more lines smaller with E-ETDRS in 5 (4%).
STATISTICAL ANALYSES
Differences in patient characteristics for those participating in the extension study vs those not participating were evaluated to discover potential bias. Amblyopic eye and sound eye visual acuity was compared between randomized treatment groups as a continuous variable in analysis of covariance models adjusted for baseline acuity. A logistic regression model was used to compare the proportions of eyes in each treatment group with amblyopic eye visual acuity of 20/25 or better. Seven patients who completed the age 10 years outcome examination but had visual acuity tested with a method other than the E-ETDRS protocol were not included in the primary visual acuity analysis. An analysis that included the visual acuity data from the 7 patients produced results similar to the primary analysis (data not shown). The exact Wilcoxon rank sum test was used to compare stereoacuity scores in the treatment groups.
Change in interocular acuity difference between the 6-month and 2-year postrandomization examinations and between the 2-year postrandomization examination and the age 10 years examination was evaluated with paired-sample t tests. The associations between amblyopic eye visual acuity at the age 10 years outcome and baseline variables (cause of amblyopia, age at randomization, and prior treatment) were evaluated in analysis of covariance models that adjusted for baseline visual acuity, with the age 10 years visual acuity score as the dependent variable.
RESULTS
The age 10 years examination was completed by 176 of the 188 patients (94%). Their mean age was 5.2 years (age range, 2.6-6.9 years) at enrollment and 10.3 years (age range, 9.2-11.9 years) at the age 10 years examination; 41% were female. The mean visual acuity of the amblyopic eyes at entry into the randomized trial was 0.53 logMAR (approximately 20/63), with a mean interocular difference in acuity of 4.5 lines. The cohort was comparable to randomized patients who did not participate in the extension study in terms of age, race, sex, cause of amblyopia (anisometropia, strabismus, or a combined mechanism), baseline visual acuity in the amblyopic and sound eyes, baseline interocular acuity difference, baseline mean spherical equivalent refractive error, prior treatment before randomization, and randomized treatment group. However, patients who participated in the extension study had better amblyopic eye visual acuity at the 2-year outcome examination than patients who did not participate in the extension study (mean logMAR acuity, 0.14 vs 0.19).
TREATMENT PRESCRIBED
Between the 6-month examination and the age 10 years examination, 89% of the children were prescribed some form of amblyopia treatment other than spectacles for at least part of the time. For 66% of the children who were treated, no treatment other than the treatment assigned through randomization was prescribed (ie, patching was the only treatment prescribed for those randomized to the patching group and atropine was the only treatment prescribed for those randomized to the atropine group). Of the patients, 33% received the alternative treatment (ie, randomized to patching but prescribed atropine after the 6-month examination or randomized to atropine but prescribed patching). At the age 10 years examination, 88% of children had received no treatment for amblyopia within the prior year, 4% had received patching, 5% had received atropine or other pharmacologic penalization, and 3% reported receiving both atropine and patching.
VISUAL ACUITY AT THE AGE 10 YEARS EXAMINATION
At the age 10 years examination, visual acuity was measured according to protocol in 169 patients (90% of those enrolled). The mean amblyopic eye acuity was 0. Table 1) . Amblyopic eye visual acuity was similar in the 2 original treatment groups (difference in visual acuity between the treatment groups adjusted for baseline acuity was −0.01 logMAR; 95% confidence interval, −0.06 to 0.03) ( Table 2 ). The amblyopic eye had an acuity of 20/25 or better in 42% of patients originally prescribed patching and in 49% of patients originally prescribed atropine (P=.74) ( Table 2 ). The mean sound eye acuity was −0.03 logMAR in each group (approximately 20/20), and the difference between the treatment groups adjusted for baseline acuity was 0 logMAR (95% confidence interval, −0.03 to 0.02; P =.80).
Younger age at entry into the randomized trial was associated with a better amblyopic eye visual acuity at age 10 years. The mean visual acuity at the age 10 years examination was 0.14 (approximately 20/25−2) in the 68 patients younger than 5 years at randomization compared with 0.20 (approximately 20/32) in the 101 patients 5 years or older at randomization (P Ͻ .001); 57% of the patients younger than 5 years at randomization tested 20/25 or better compared with 38% of patients 5 years or older at randomization (P=.004). No apparent relation was found between cause of amblyopia (strabismus, anisometropia, or a combined mechanism) and the age 10 years outcome visual acuity (P=.83).
STEREOACUITY AT THE AGE 10 YEARS EXAMINATION
The median stereoacuity at the age 10 years examination, measured with the Randot Preschool Stereoacuity Test, was 400 arc seconds among all patients and 100 arc seconds among patients classified at baseline as having Abbreviations: E-ETDRS, electronic modification of the testing protocol developed for the Early Treatment Diabetic Retinopathy Study; logMAR, logarithm of the minimum angle of resolution; NA, not applicable.
a At 6 months and 2 years after randomization, visual acuity was measured with the HOTV Amblyopia Treatment Study visual acuity testing protocol. At the age 10 years examination, visual acuity was measured with the E-ETDRS protocol. Seven patients measured with techniques other than E-ETDRS at the age 10 years examination are excluded from this table. When the HOTV Amblyopia Treatment Study protocol was used, interocular acuity was calculated as the difference between the amblyopic eye and sound eye logMAR line acuities, whereas at the age of 10 years when E-ETDRS was used, the interocular acuity was calculated as the difference between the amblyopic eye and sound eye letter scores, rounded to the nearest logMAR line. a Data are given as percentage of each group. The mean (SD) logMAR overall was 0.17 (0.15); in the patching group, 0.19 (0.14); and in the atropine group, 0.16 (0.16). The difference between randomized treatment groups in mean logMAR acuity at the age 10 years examination adjusted for baseline visual acuity in analysis of covariance model was −0.01 (95% confidence interval, −0.06 to 0.03). A positive difference indicates that the mean patching group scores were better than the mean atropine group scores.
b Seven patients were tested with other methods of acuity testing not in listed in the table (5 with HOTV purely anisometropic amblyopia. Results were similar in the 2 treatment groups (P = .87 overall and P = .78 for patients with anisometropic amblyopia) ( Table 3) .
COMMENT
Most of the improvement with patching or atropine treatment appears to be maintained until age 10 years. However, approximately half of children with moderate amblyopia (visual acuity, 20/40-20/100) initially treated at age 3 years to younger than 7 years have mild residual amblyopia at age 10 years (visual acuity, Ͻ20/25). Outcomes were similar in the original treatment groups of atropine and patching. The outcome was slightly better in patients who were aged 3 years to younger than 5 years at enrollment compared with those aged 5 years to younger than 7 years. This outcome could be because younger age at initiation of treatment might be advantageous if plasticity decreases with age or a shorter duration of amblyogenic insult might reduce the severity of the effect on the visual sensory system. We had not observed an age relationship at younger ages in the full randomized cohort, 3, 13 and it is possible that the apparent age effect at the age 10 years examination in our limited cohort may be because of chance. We intend to evaluate this effect again at the final age 15 years examination.
Our study design included measurement of stereoacuity to determine whether the amblyopia treatments had different effects on the development of binocularity. Simons et al 16 suggested a beneficial effect for atropine in a nonrandomized study using various atropine dosages. Conversely, Kushner 17 has voiced concern about a possible negative effect of persistent cycloplegia on binocularity. At the age 10 years outcome examination, we found no difference in stereoacuity outcome between children originally treated with patching and those originally treated with atropine, whether analyzed overall or when the analysis was restricted to the children with pure anisometropic amblyopia.
At age 10 years, many children had residual amblyopia despite careful treatment and follow-up within a clinical trial. No standardized approach to treatment for residual amblyopia was used by study investigators during the follow-up. In a future trial, we intend to investigate the management of residual amblyopia to determine whether increased intensity of treatment, including combined therapies, would further reduce the visual acuity deficit in the amblyopic eye.
Recurrence of amblyopia has been commonly reported after reduction or cessation of amblyopia treatment. During the first year after treatment reduction, rates of recurrence of 24% to 27% have been reported. 12, 18, 19 With longer follow-up, higher recurrence rates of up to 58% have been reported. 9, 10, [20] [21] [22] Between the 6-month and age 10 years examinations of our clinical trial, 89% of patients were treated for some period. However, 88% of the children received no treatment during the year before the age 10 years examination. Because children were treated at investigator discretion, including use of spectacles after the initial treatment episode, our data cannot be used to estimate the chance of recurrence when all therapy is discontinued. In addition, we cannot directly compare our measurements of visual acuity at the earlier study visits (6 months and 2 years after randomization) with those at the age 10 years examination because different methods were used to measure visual acuity. Although the interocular difference was greater at the age 10 years examination using the E-ETDRS protocol than at the 2-year examination using the HOTV Amblyopia Treatment Study protocol, our data directly comparing the 2 methods (see the "Visual Acuity Testing" subsection of the "Methods" section) suggest that this difference was because of the different testing methods and not a true worsening of visual acuity.
In our previous report, 3 after 6 months of treatment, more patients in the atropine-treated group than in the patching group had a transient reduction in visual acuity of the sound eye. We concluded that some of this reduction was likely due to persistent cycloplegia and incorrect spectacle correction when the visual acuity was measured. 3 Once the problem was recognized, the sound eye testing protocol was revised to increase the time not taking atropine to 2 weeks before sound eye visual acu- ity testing. The sound eye acuity difference by treatment group was not observed at either the 2-year outcome visit 13 or the age 10 years examination. Our results are subject to potential selection bias in that patients who participated had better amblyopic eye visual acuity at the 2-year outcome examination than patients who did not participate (approximately 3 letters on average better). As a result, our observed amblyopic eye acuity at the age of 10 years may be slightly overestimated. We could not identify other sources of bias to
